Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Fifth partial response confirmed in ACCENT trial
Amplia receives R&D Tax Rebate
Key chemical form patents in Europe and Japan
Fourth partial response confirmed in ACCENT trial
ASX Briefs podcast | Interview with Dr Chris Burns
Categories
Archive
Company News
Investor Newsletters
Videos
28 Feb 2023
ACCENT Trial Recruitment Progress | Cohort 2 filled
Read More
13 Feb 2023
Women in Science | Q&A with Dr Terrie-Anne Cock, Head of Translational Biology
Read More
09 Feb 2023
35th Annual Lorne Cancer Conference, 9-11 February 2023
Read More
06 Feb 2023
Channel 9 News | 3 February 2023
Read More
06 Feb 2023
The Courier Mail | New hope for advanced pancreatic cancer patients in clinical trials
Read More
06 Feb 2023
ABC Media Coverage | Pancreatic cancer clinical trial opens in Queensland, offering hope to patients
Read More
01 Feb 2023
First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer
Read More
1